Digoxin Suppresses Tumor Malignancy through Inhibiting Multiple Src-Related Signaling Pathways in Non-Small Cell Lung Cancer


Non-small cell lung cancer is the predominant type of lung cancer, resulting in high mortality worldwide. Digoxin, a cardiac glycoside, has recently been suggested to be a novel chemotherapeutic agent. Src is an oncogene that plays an important role in cancer progression and is therefore a potential target for cancer therapy. Here, we investigated whether… (More)
DOI: 10.1371/journal.pone.0123305

6 Figures and Tables



Citations per Year

Citation Velocity: 10

Averaging 10 citations per year over the last 2 years.

Learn more about how we calculate this metric in our FAQ.
  • Presentations referencing similar topics